Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Li, Qiaoqiao ^a   Hu, Yonghong ^a   Xi, Mian ^a   He, Liru ^a   Zhao, Lei ^a   Liu, Mengzhong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Apoptosis; DNA damage repair; Hepatocellular carcinoma; Radiation; Sorafenib

Indexed keywords

SORAFENIB;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; LIVER CELL CARCINOMA; RADIOSENSITIVITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84867658134     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-485     Document Type: Article

References (22)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2(9):533-543. 10.1016/S1470-2045(01)00486-7, 11905707.
2. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005, 5(2):131-138. 10.2174/1568009053202063, 15810877.
3. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, Knol J, Dawson LA, Pan C, Lawrence TS. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005, 23(34):8739-8747. 10.1200/JCO.2005.01.5354, 16314634.
4. Seong J, Lee IJ, Shim SJ, Lim Do H, Kim TH, Kim JH, Jang HS, Kim MS, Chie EK, Nam TK, et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009, 29(2):147-152. 10.1111/j.1478-3231.2008.01873.x, 18795897.
5. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, Yoo BC, Lee JE, Kang MK, Park YJ, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005, 61(4):1143-1150. 10.1016/j.ijrobp.2004.08.028, 15752895.
6. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005, 41(12):773-784.
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390. 10.1056/NEJMoa0708857, 18650514.
9. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66(24):11851-11858. 10.1158/0008-5472.CAN-06-1377, 17178882.
10. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007, 67(19):9443-9454. 10.1158/0008-5472.CAN-07-1473, 17909054.
11. Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, Robertson JM, Wilson GD. Sorafenib and radiation: a promising combination in colorectal cancer. Int J Radiat Oncol Biol Phys 2010, 78(1):213-220. 10.1016/j.ijrobp.2010.02.064, 20708486.
12. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007, 5(4):291-294. 10.3816/CGC.2007.n.007, 17553211.
13. Hsieh CH, Jeng KS, Lin CC, Chen CK, Liu CY, Lin CP, Tai HC, Wang CH, Shueng PW, Chen YJ. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009, 29(1):65-71. 10.2165/0044011-200929010-00007, 19067476.
14. Zhang Y, Chen LH, Wang L, Wang HM, Zhang YW, Shi YS. Radiation-inducible PTEN expression radiosensitises hepatocellular carcinoma cells. Int J Radiat Biol 2010, 86(11):964-974. 10.3109/09553002.2010.496032, 20677905.
15. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G, Liu Q, Pei D, Kang T, Zeng YX. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem 2010, 285(7):4931-4940. 10.1074/jbc.M109.048397, 2836097, 20007324.
16. Cao JX, Cui YX, Long ZJ, Dai ZM, Lin JY, Liang Y, Zheng FM, Zeng YX, Liu Q. Pluripotency-associated genes in human nasopharyngeal carcinoma CNE-2 cells are reactivated by a unique epigenetic sub-microenvironment. BMC Cancer 2010, 10:68. 10.1186/1471-2407-10-68, 2837014, 20181293.
17. Deng R, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, Zhu XF. ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther 2009, 8(4):873-882. 10.1158/1535-7163.MCT-08-1080, 19372560.
18. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol 2010, 31(4):363-372. 10.1007/s13277-010-0042-8, 20490962.
19. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401(6753):616-620. 10.1038/44188, 10524633.
20. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23(16):2825-2837. 10.1038/sj.onc.1207528, 15077146.
21. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 2004, 3(8-9):997-1007.
22. Cann KL, Hicks GG. Regulation of the cellular DNA double-strand break response. Biochem Cell Biol 2007, 85(6):663-674. 10.1139/O07-135, 18059525.